First Time Loading...

ICON PLC
NASDAQ:ICLR

Watchlist Manager
ICON PLC Logo
ICON PLC
NASDAQ:ICLR
Watchlist
Price: 325.51 USD 1.53% Market Closed
Updated: Mar 2, 2024

Intrinsic Value

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. [ Read More ]

The intrinsic value of one ICLR stock under the Base Case scenario is 326.49 USD. Compared to the current market price of 325.51 USD, ICON PLC is Fairly Valued.

Key Points:
ICLR Intrinsic Value
Base Case
326.49 USD
Fairly Valued
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ICON PLC

Backtest ICLR Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ICLR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Firm Projects Revenue and Earnings Growth in 2024
2023-Q4 Earnings Call

Firm Projects Revenue and Earnings Growth in 2024

Following a robust fourth quarter and a favourable start to the year, the company reaffirms its full-year 2024 financial guidance. Revenue is anticipated to grow between 3.4% to 8.4% from 2023, reaching $8.4 billion to $8.8 billion. Adjusted earnings per share are expected to increase by 13.4% to 19.6%, resulting in a range of $14.50 to $15.30.

Financials

Balance Sheet Decomposition
ICON PLC

Current Assets 3.4B
Cash & Short-Term Investments 380.1m
Receivables 2.9B
Other Current Assets 132.1m
Non-Current Assets 13.6B
Long-Term Investments 46.8m
PP&E 501.5m
Intangibles 12.9B
Other Non-Current Assets 152.1m
Current Liabilities 2.8B
Accounts Payable 131.6m
Accrued Liabilities 36.4m
Other Current Liabilities 2.7B
Non-Current Liabilities 4.9B
Long-Term Debt 3.7B
Other Non-Current Liabilities 1.3B
Efficiency
Fundamental Scores

ICLR Profitability Score
Profitability Due Diligence

ICON PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Free Cash Flow
Positive Gross Profit
Positive Revenue Growth Forecast
53/100
Profitability
Score

ICON PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

ICLR Solvency Score
Solvency Due Diligence

ICON PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
44/100
Solvency
Score

ICON PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ICLR Price Targets Summary
ICON PLC

Wall Street analysts forecast ICLR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ICLR is 351.27 USD with a low forecast of 287.85 USD and a high forecast of 404.25 USD.

Lowest
Price Target
287.85 USD
12% Downside
Average
Price Target
351.27 USD
8% Upside
Highest
Price Target
404.25 USD
24% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ICLR Price
ICON PLC

1M 1M
+25%
6M 6M
+26%
1Y 1Y
+41%
3Y 3Y
+89%
5Y 5Y
+135%
10Y 10Y
+592%
Annual Price Range
325.51
52w Low
183.12
52w High
325.51
Price Metrics
Average Annual Return 13.81%
Standard Deviation of Annual Returns 36.73%
Max Drawdown -35%
Shares Statistics
Market Capitalization 26.9B USD
Shares Outstanding 82 495 104
Percentage of Shares Shorted 2.47%

ICLR Return Decomposition
Main factors of price return

What is price return decomposition?

ICLR News

Other Videos

Company Profile

ICON PLC Logo
ICON PLC

Country

Ireland

Industry

Life Sciences Tools & Services

Market Cap

26.9B USD

Dividend Yield

0%

Description

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 38,330 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. The firm specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The company conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The firm offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Contact

DUBLIN
DUBLIN
South County Business Park, Dublin 18
+35312912000.0
http://www.iconplc.com/

IPO

1998-05-15

Employees

38 330

Officers

Chief Financial Officer
Mr. Brendan Brennan

See Also

Discover More
What is the Intrinsic Value of one ICLR stock?

The intrinsic value of one ICLR stock under the Base Case scenario is 326.49 USD.

Is ICLR stock undervalued or overvalued?

Compared to the current market price of 325.51 USD, ICON PLC is Fairly Valued.